Axsome Therapeutics Stock Performance

AXSM Stock  USD 181.21  1.73  0.95%   
On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of -0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Axsome Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(0.95)
Five Day Return
(0.99)
Year To Date Return
1.41
Ten Year Return
2.1 K
All Time Return
K
1
Quadrature Capital Ltd Boosts Holdings in Axsome Therapeutics, Inc. AXSM - MarketBeat
12/01/2025
2
Behavioral Patterns of AXSM and Institutional Flows - Stock Traders Daily
12/29/2025
3
Disposition of 31261 shares by Tabuteau Herriot of Axsome Therapeutics at 170.38 subject to Rule 16b-3
01/07/2026
4
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
01/15/2026
5
Disposition of 15000 shares by Mark Jacobson of Axsome Therapeutics at 4.85 subject to Rule 16b-3
01/16/2026
6
Axsome Therapeutics Appears In Nasdaq Today CNS Discussions
01/20/2026
7
Axsome Therapeutics Valuation Check After Strong Recent Share Price Momentum
01/21/2026
8
Disposition of 12000 shares by Pizzie Nick of Axsome Therapeutics at 187.92 subject to Rule 16b-3
01/22/2026
9
Piper Sandler Bullish on Axsome Therapeutics Ahead of Likely Auvelity Label Expansion by April 30
01/23/2026
10
Axsome Therapeutics Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway
01/28/2026
11
Disposition of 32410 shares by Tabuteau Herriot of Axsome Therapeutics at 185.6 subject to Rule 16b-3
02/02/2026
12
Axsome Therapeutics Reports 66 percent Revenue Growth in FY2025, Beats Analyst Estimates
02/03/2026
13
Should You Buy Axsome Therapeutics Stock Before Feb. 23
02/05/2026
14
Disposition of 5193 shares by Coleman Mark of Axsome Therapeutics at 8.02 subject to Rule 16b-3
02/10/2026
15
Factors You Need to Know Ahead of ProPetros Q4 Earnings Release
02/13/2026
Begin Period Cash Flow386.2 M
Total Cashflows From Investing Activities-270 K

Axsome Therapeutics Relative Risk vs. Return Landscape

If you would invest  14,556  in Axsome Therapeutics on November 17, 2025 and sell it today you would earn a total of  3,565  from holding Axsome Therapeutics or generate 24.49% return on investment over 90 days. Axsome Therapeutics is currently generating 0.4062% in daily expected returns and assumes 3.4194% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Axsome, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Axsome Therapeutics is expected to generate 4.48 times more return on investment than the market. However, the company is 4.48 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Axsome Therapeutics Target Price Odds to finish over Current Price

The tendency of Axsome Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 181.21 90 days 181.21 
about 15.21
Based on a normal probability distribution, the odds of Axsome Therapeutics to move above the current price in 90 days from now is about 15.21 (This Axsome Therapeutics probability density function shows the probability of Axsome Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Axsome Therapeutics has a beta of -0.15. This suggests as returns on the benchmark increase, returns on holding Axsome Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Axsome Therapeutics is likely to outperform the market. Additionally Axsome Therapeutics has an alpha of 0.4655, implying that it can generate a 0.47 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Axsome Therapeutics Price Density   
       Price  

Predictive Modules for Axsome Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Axsome Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
179.86183.31186.76
Details
Intrinsic
Valuation
LowRealHigh
163.09193.81197.26
Details
19 Analysts
Consensus
LowTargetHigh
196.05215.44239.14
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.910.091.25
Details

Axsome Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Axsome Therapeutics is not an exception. The market had few large corrections towards the Axsome Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Axsome Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Axsome Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.47
β
Beta against Dow Jones-0.15
σ
Overall volatility
17.58
Ir
Information ratio 0.12

Axsome Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Axsome Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Axsome Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Axsome Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M.
Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Axsome Therapeutics has a frail financial position based on the latest SEC disclosures
Over 77.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Factors You Need to Know Ahead of ProPetros Q4 Earnings Release

Axsome Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Axsome Stock often depends not only on the future outlook of the current and potential Axsome Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Axsome Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding47.9 M
Cash And Short Term Investments315.4 M

Axsome Therapeutics Fundamentals Growth

Axsome Stock prices reflect investors' perceptions of the future prospects and financial health of Axsome Therapeutics, and Axsome Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axsome Stock performance.

About Axsome Therapeutics Performance

By examining Axsome Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Axsome Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axsome Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 198.29  252.16 
Return On Tangible Assets(0.51)(0.53)
Return On Capital Employed(0.75)(0.78)
Return On Assets(0.45)(0.48)
Return On Equity(5.79)(6.08)

Things to note about Axsome Therapeutics performance evaluation

Checking the ongoing alerts about Axsome Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Axsome Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Axsome Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M.
Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Axsome Therapeutics has a frail financial position based on the latest SEC disclosures
Over 77.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Factors You Need to Know Ahead of ProPetros Q4 Earnings Release
Evaluating Axsome Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Axsome Therapeutics' stock performance include:
  • Analyzing Axsome Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axsome Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Axsome Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Axsome Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axsome Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Axsome Therapeutics' stock. These opinions can provide insight into Axsome Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Axsome Therapeutics' stock performance is not an exact science, and many factors can impact Axsome Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.68)
Revenue Per Share
11.402
Quarterly Revenue Growth
0.632
Return On Assets
(0.20)
Return On Equity
(2.75)
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.